Virios Therapeutics, Inc. (NASDAQ:VIRI – Get Free Report)’s stock price was down 1.7% during mid-day trading on Monday . The company traded as low as $1.60 and last traded at $1.69. Approximately 116,264 shares were traded during mid-day trading, a decline of 89% from the average daily volume of 1,049,645 shares. The stock had previously closed at $1.72.
Virios Therapeutics Trading Down 5.6%
The business’s 50-day simple moving average is $1.93 and its 200-day simple moving average is $1.90. The company has a market capitalization of $29.08 million, a PE ratio of -5.59 and a beta of 1.58.
About Virios Therapeutics
Virios Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antiviral therapies for diseases that may be associated with abnormal activation or reactivation of herpes-family viruses. The company’s research is based on the premise that viral activity can contribute to chronic inflammatory and pain-related conditions.
Virios’ lead investigational product is IMC-1, a fixed-dose combination of famciclovir and celecoxib being developed for the treatment of fibromyalgia.
Featured Stories
- Five stocks we like better than Virios Therapeutics
- Chips to Bots: Qualcomm’s Agentic AI Breakout
- Ciena Fell 40%—Now One Analyst Sees 50% Upside
- Energy Transfer Taps the AI Power Boom
- Viking’s Obesity Edge May Be Staying Power, Not Weight Loss
Receive News & Ratings for Virios Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virios Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
